Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor

Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline. http://www.worldpharmanews.com/novartis/3531-novartis-adds-bispecific-antibodies-to-its-growing-immuno-oncology-portfolio-through-collaboration-and-licensing-agreement-with-xencor